KYMR Kymera Therapeutics, Inc.
$117.57▲ +2.38%
Healthcare
Other
After hours
$117.57▲ +0.00%
Oct 27, 4:53 PM ET
Volume 827.9K
Avg Volume (10D) 736.8K
Key Metrics & Fundamentals
Market Cap
$9.67B
P/E Ratio
–
Div Yield
0.00%
52W Range
55.66 - 130.05
% vs 50 MA
2.34%
% vs 200 MA
22.89%
RSI-14
59.4
MACD Histogram
+1.0700
Beta (1Y vs SPY)
0.77
Free Cash Flow
-$54.54M
Gross Rev
$65.00M
Gross Profit
$65.00M
EBITDA
-$59.10M
COGS
–
Operating Exp
$140.61M
Operating Income
-$75.61M
EBIT
-$75.61M
Pretax Income
-$61.21M
Net Income
-$61.21M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
Kymera Therapeutics (KYMR) Nears Earnings With KT 621 In Focus, Is The Stock Still Cheap?
Simply Wall St. · Oct 27, 2026 6:16 PM ET
Could You Have Seen The Run In Kymera Stock Coming?
Trefis · Oct 26, 2026 5:34 PM ET
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
Zacks · Oct 26, 2026 9:00 AM ET
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
GlobeNewswire · Oct 22, 2026 4:01 PM ET
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Zacks · Oct 19, 2026 9:08 AM ET
Big Pharma Is Pouring Billions Into a New Class of ‘Protein Degrader’ Drugs
The Wall Street Journal · Oct 15, 2026 5:30 AM ET
BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123
MT Newswires · Sep 14, 2026 8:21 AM ET
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Zacks · Sep 4, 2026 11:30 AM ET
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Zacks · Sep 3, 2026 11:50 AM ET
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · Sep 2, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See KYMR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.